Filing Flows › Autolus Therapeutics (AUTL) › Q3 2025
Autolus Therapeutics (AUTL) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 12, 2025
Autolus Therapeutics (AUTL) reported revenue of $21.2M for the third quarter 2025 (Q3 2025) and +1% from the quarter before. Operating margin was -337.9%, net loss $79.1M (373.3% of revenue).
Autolus Therapeutics, Q3 2025: revenue $21.2M, operating margin -337.9%, net loss $79.1M, operating cash flow −$67.9M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $21.2M | +1% | — |
| Operating profit | −$71.6M | — | — |
| Net earnings | −$79.1M | — | — |
| Operating cash flow | −$67.9M | — | — |
What changed
Revenue was $21.2M in Q3 2025, up 1% from the previous quarter. Product revenue, net was the largest line at 100% of revenue.
Operating costs exceeded revenue by $71.6M, an operating margin of -337.9%. The quarter ended with a net loss of $79.1M, wider than the previous quarter's $47.9M loss.
Operating cash flow was −$67.9M. Non-cash charges added back $2.1M of depreciation and amortization and $3.8M of share-based compensation. Working capital and other items added $5.3M. Capital expenditures of $4.4M exceeded it, leaving free cash flow of −$72.3M.
Questions
What was Autolus Therapeutics' revenue in the third quarter 2025?
Autolus Therapeutics (AUTL) reported revenue of $21.2M for the third quarter 2025 (Q3 2025) and +1% from the quarter before.
Was Autolus Therapeutics profitable in the third quarter 2025?
Operating loss was $71.6M (-337.9% of revenue) and net loss $79.1M.